SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Medicenna Therapeutics Corp. MDNA NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • CA • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Medicenna Therapeutics Corp. (MDNA) is a Biotechnology company in the Healthcare sector, currently trading at $0.16. It has a SharesGrow Score of 60/100, indicating a above average investment profile with 3 out of 7 criteria passed.

Net income is $2M, growing at -10.6%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $0 against $29M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 9.58 (strong liquidity). Debt-to-assets is 0%. Total assets: $36M.

Analyst outlook: 2 / 2 analysts rate MDNA as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 25/100 (Fail), Health 100/100 (Pass), Moat 28/100 (Fail), Future 100/100 (Pass), Income ?/100 (Fail).

MDNA SharesGrow Score Overview

61/100

SharesGrow Score

Above average fundamentals

View full scorecard →

VALUE 100/100

Valuation — P/E, PEG, Forward PEG

GROWTH 15/100

Financials — average growth

PAST 25/100

strong — trend

HEALTH 100/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 28/100

Gross margin is + market cap

FUTURE 100/100

Analyst outlook — as buy

INCOME 0/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — MDNA

MDNA trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

MDNA: +0%/yr revenue is, -10.6%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

MDNA: 1 / 4 years profitable. weak. Score = 1 / 4 × 100. ≥ 80 = Pass.

View details →

Balance sheet MDNA: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 9.58 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

MDNA: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.

View details →

Analyst outlook: 2 / 2 analysts rate MDNA as buy (100%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

No analyst coverage available for this stock.

Stock Chart & Stats

Market Data

52-Week Range0.15125-0.1999

Volume1.26M

Avg Volume (30D)1.26M

Beta (1Y)0.77

Share Statistics

EPS (TTM)0.02

Shares Outstanding$64.74M

IPO Date2017-11-13

Employees16

CEOFahar Merchant

Financial Highlights & Ratios

EBITDA$-16.3M

Net Income$1.55M

Operating Income$-16.3M

Total Cash$33.6M

Net Debt$-33.6M

Total Assets$36.45M

Price / Earnings (P/E)6.6

Analyst Forecast

Rating ConsensusBuy

Analysts Covering2

Buy 100% Hold 0% Sell 0%

Company Info

CountryCA

ExchangeNASDAQ Capital Marke

CurrencyUSD

ISINCA58490H1073

Price Chart

MDNA

Medicenna Therapeutics Corp. ↗ · NASDAQ Capital Marke

Healthcare • Biotechnology

0.15 52WK RANGE 0.20

People Also View

Edgewise Therapeutics, Inc.

Ikena Oncology, Inc.

Ovid Therapeutics Inc.

Monopar Therapeutics Inc.

Checkpoint Therapeutics, Inc.

Eliem Therapeutics, Inc.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message